Literature DB >> 20423649

[pCTLA4-Ig gene-modified porcine immature dendritic cells inhibit the proliferation of xenogeneic spleen cells].

Min Tian1, Yi Lü, Chao Zhai, Hai-tao Zhu, Bo Wang, Liang Yu, Xiao-gang Zhang.   

Abstract

AIM: To establish a method for induced and amplified porcine monocyte-derived immature dendritic cells(imDCs).The aim of this study was to assess the pCTLA4-Ig gene-modified porcine imDCs could benefit for prevent the proliferation of xenogeneic spleen cells.
METHODS: Poricne peripheral blood mononuclear cells(PBMC) were cultured with rpGM- CSF(30 microg/L) and rpIL-4(20 microg/L). To evaluate the suspending cells by transmission electronic microscope and flow cytometer. Porcine imDCs were transduced with adenovirus mediated pCTLA4-Ig gene. The mixed lymphocyte reaction(MLR) was used to examine the proliferation of spleen cells of SD rat to gene-modified imDCs.
RESULTS: With rpGM-CSF and rpIL-4 induced porcine PBMC for 4-5 days, it was exhibited typical morphological characteristics and immunological phenotype of imDCs with high expression of SLA-DR, CD172a and low expression of CD80/CD86 on the cellular surface. The gene-modified imDCs were able to amplified the pCTLA4-Ig and IDO gene by RT-PCR. The stimulate index of gene-modified imDCs group were markedly inferior to that in unmodified imDCs group(P<0.05).
CONCLUSION: The pCTLA4-Ig gene-modified imDCs can significantly inhibit the proliferation of xenogeneic spleen cells, and there might was correlated with the expression of IDO reduce the immune response of xenogeneic antigen.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20423649

Source DB:  PubMed          Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi        ISSN: 1007-8738


  1 in total

1.  Alternative immunomodulatory strategies for xenotransplantation: CD80/CD86-CTLA4 pathway-modified immature dendritic cells promote xenograft survival.

Authors:  Min Tian; Yi Lv; Chao Zhai; Haitao Zhu; Liang Yu; Bo Wang
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.